Paris – 10 April 2014 – EnterNext, the Euronext subsidiary designed to promote and grow its market for SMEs[1], today congratulated Quantum Genomics, a biopharmaceutical research company developing new therapies for cardiovascular disease, on its transfer from the Free Market to Alternext in Paris following a €3.4 million private placement.
Quantum Genomics is a biopharmaceutical company that develops new therapies for unmet medical needs in the treatment of cardiovascular disease, in particular high blood pressure and heart failure. The company has built a balanced portfolio of candidate drugs using a new therapeutic approach based on Brain Aminopeptidase A Inhibition, developed through over 20 years of research at the Collège de France, INSERM and CNRS.
Quantum Genomics (new ticker symbol: ALGTCL) was listed through the admission to trading on Alternext Paris of 4,747,403 shares making up the company’s equity, including 637,334 newly issued shares resulting from a private placement of around €3.4 million with qualified investors at the unit price of €5.35.
“We congratulate Quantum Genomics on the milestone represented by its successful listing on Alternext, Euronext’s self-regulated market,”said Eric Forest, Chairman and CEO of EnterNext. “This transfer will boost Quantum Genomics’ visibility with larger number of investors. EnterNext will continue to accompany the company as it works to achieve its aims.”
Lionel Ségard, Chairman and CEO of Quantum Genomics, added: “This capital increase is part of our long-term goal of building a shareholder base with investors prepared to participate in Quantum Genomics’ growth and the financing of our research programmes. In the short term, funds raised will enable us to recruit more experts and start clinical phase II testing of our most advanced product for fighting high blood pressure.”